Open AccessThe effect of CPAP therapy on insulin‐like growth factor and cognitive functions in obstructive sleep apnea patients
Author(s) -
Kanbay Asiye,
Demir Neslihan Cerrah,
Tutar Nuri,
Köstek Osman,
Özer Şimşek Zuhal,
Buyukoglan Hakan,
Demir Ramazan,
Parrino Liborio
Publication year - 2017
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.12365
Subject(s) - medicine , continuous positive airway pressure , obstructive sleep apnea , polysomnography , morning , gastroenterology , apnea
Objectives Cognitive impairment is common among patients with obstructive sleep apnea syndrome (OSAS). In this study, we aimed to investigate the effect of continuous positive airway pressure (CPAP) therapy on serum insulin‐like growth factor‐1 (IGF‐1) levels and cognitive functions in patients with OSAS. Patient/Methods : Thirty‐three patients with newly diagnosed OSAS and 17 healthy‐control subjects enrolled in the study. All individuals completed the mini‐mental state examination (MMSE) to evaluate cognitive function. Blood samples were taken at the end of the polysomnography in the morning and the same procedures were repeated 3 months after starting CPAP treatment. Results In the OSAS group, the baseline MMSE score was 23.5 ± 3.6, and serum IGF‐1 level was 79.1 ± 36.1 ng/mL. Both values were significantly lower compared with the control group (mean MMSE score = 28.1 ± 1.4, P = 0.0001; mean serum IGF‐1 level = 147.1 ± 49.1 ng/mL, P < 0.0001). Three months after CPAP treatment, OSAS patients showed a significant improvement in MMSE scores (26.5 ± 2.8, P = 0.0001) and serum IGF‐1 level (129.1 ± 58.2, P = 0.0001). In contrast, baseline and third‐month measurements for IGF‐1 levels and MMSE scores were not significantly different in the control group. Conclusions The results indicate that effective CPAP therapy in OSAS patients leads to significant improvement in cognitive functions and IGF‐1 even in a short‐term follow‐up. Cognitive function assessment might be a part of evaluation in OSAS patients.